Lee's Pharmaceutical Holdings Limited

950 KYG5438W1116

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 01:38:30 12/01/2026 pm IST			5-day change	1st Jan Change
1.600 ^HKD	-1.84%		-0.62%	+5.26%

18/12	Lee's Pharmaceutical Holdings Limited Announces the Passing of Mr. Michele Dalla Libera, Senior Director of Business Development, on 15 December 2025	CI
09/12	Lee's Pharmaceutical Holdings Limited acquires Staccato One Breath technology platform and assets, driving pipeline expansion and advancing global partnership with UCB through acquired rights	RE

Lee's Pharmaceutical says unit buys assets for US$15 million

Published on 12/09/2025 at 06:18 am IST

Reuters

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Lee's Pharmaceutical Holdings Limited

18/12	Lee's Pharmaceutical Holdings Limited Announces the Passing of Mr. Michele Dalla Libera, Senior Director of Business Development, on 15 December 2025	CI
09/12	Lee's Pharmaceutical Holdings Limited acquires Staccato One Breath technology platform and assets, driving pipeline expansion and advancing global partnership with UCB through acquired rights	RE
09/12	Lee's Pharmaceutical says unit buys assets for US$15 million	RE
09/12	Lee's Pharmaceutical Holdings Limited signed asset purchase agreement to acquire Assets relating to Alexza Business of Alexza Pharmaceuticals, Inc., for $15 million.	CI
15/25/15	Lee's Pharma Grants Nearly 1.8 Million Share Options Under Incentive Scheme	MT
26/25/26	Lee's Pharmaceutical Holdings Limited Reports Earnings Results for the Half Year Ended June 30, 2025	CI
26/25/26	Lee's Pharmaceutical Holdings Limited Announces Ordinary Interim (Semi-Annual) Dividend for the Six Months Ended 30 June 2025, Payable 3 October 2025	CI
31/25/31	Lee's pharmaceutical says socazolimab approved for marketing by NMPA	RE
27/25/27	Lee's Pharmaceutical Holdings Limited Recommends Final Dividend for the Year Ended 31 December 2024, Payable on 16 June 2025	CI
27/25/27	Lee's Pharmaceutical Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2024	CI
19/25/19	Lee's Pharmaceutical Sees Profit Between HK$83 Million To HK$106 Million For Year	RE
19/25/19	Lee's Pharmaceutical Holdings Limited Provides Earnings Guidance for the Year Ended 31 December 2024	CI
15/24/15	Lee's Pharma Unit's Therapeutic Biological Products Gets NMPA's Go-Ahead for Clinical Trials	MT
28/24/28	Lee's Pharmaceutical Holdings Limited Announces Interim Dividend for the Six Months Ended 30 June 2024, Payable on October 3, 2024	CI
28/24/28	Lee's Pharmaceutical Holdings Limited Reports Earnings Results for the Half Year Ended June 30, 2024	CI
05/24/05	Hong Kong Stocks Start Week in Red; Lee's Pharmaceutical Shares Jump 7%	MT
05/24/05	Lee's Pharmaceutical Expects Fourfold Increase in H1 Profit; Shares Jump 8%	MT
04/24/04	Lee's Pharmaceutical Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2024	CI
02/24/02	Lee's Pharmaceutical Enrolls First Patient in Phase 1 Trial for Liver Cancer Drug	MT
01/24/01	Lee's Pharmaceutical Holdings Limited Announces the First Patient Has Been Enrolled in A Phase I Clinical Trial to Receive Au409 At Queen Mary Hospital, Hong Kong	CI
02/24/02	Lee's Pharmaceutical Holdings Limited Appoints Huang Zuie Chin as A Non-Executive Director	CI
19/24/19	Lee’s Pharmaceutical's 2023 Profit Slumps 67%	MT
26/24/26	Lee's Pharmaceutical Holdings Limited Proposes Ordinary Final Dividend for the Year Ended 31 December 2023, Payable on 17 June 2024	CI
26/24/26	Lee's Pharmaceutical Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2023	CI
29/23/29	China Grants Lee's Pharmaceutical Drug Registration for Schizophrenia-Related Agitation Treatment; Shares Rise 3%	MT

Chart Lee's Pharmaceutical Holdings Limited

Duration

Period

Chart Lee's Pharmaceutical Holdings Limited

950: Dynamic Chart

Lee's Pharmaceutical Holdings Ltd is an investment holding company principally engaged in the development, manufacturing, marketing and sales of pharmaceutical products. The Company operates its business through two segments. The Imported Products segment is engaged in the sale of imported products. Its imported products include Keyan injection, Fipril oral solution and others. The Proprietary Products segment is engaged in the manufacture and sale of self-developed products. Its R&D products include Resilicon Tablets, ADASUVE Inhalation Powder and others. The Company's medicines cover the fields of cardiovascular and infectious diseases, dermatology, oncology, gynecology and ophthalmology. The Company mainly operates its business in mainland China, Hong Kong and Taiwan.

Employees

1,036

Sector

Pharmaceuticals

Calendar

26/03 - Q4 2025 Earnings Release (Projected)

More about the company